Actualités Pharming Group NV - PHARM | Actions Euronext

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders Leiden, the Netherlands, March 4, 2025: Pharming Group...

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam:...

Pharming Group to participate in March investor conference

Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq:...

Pharming Group to report fourth quarter and full year 2024 financial results on March 13

Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq:...

Pharming Group to report fourth quarter and full year 2024 financial results on March 13

Pharming Group to report fourth quarter and full year 2024 financial results on March 13 Leiden, the Netherlands, February 27, 2025: Pharming...

Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent

Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent This press release is not an offer, whether directly or...

Pharming Group to participate in February investor conference

Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq:...

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the...

Pharming Group to convene Extraordinary General Meeting of Shareholders

Pharming Group to convene Extraordinary General Meeting of Shareholders Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming”...

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT...

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer Leiden, the Netherlands...

Pharming announces public cash offer to the shareholders of Abliva AB

Pharming announces public cash offer to the shareholders of Abliva AB Proposed acquisition strengthens Pharming’s late-stage pipeline with a...

Pharming announces public cash offer to the shareholders of Abliva AB

Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset...

Pharming announces positive topline data in pediatric clinical trial of leniolisib

Pharming announces positive topline data in pediatric clinical trial of leniolisib Multinational Phase III study is evaluating leniolisib tablets...

Pharming announces positive topline data in pediatric clinical trial of leniolisib

Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharming Group NV (PHARM)

Votre Hub pour des idées et discussions en direct en temps réel

PHARM Actualités

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Pharming Group to participate in March investor conference

Pharming Group to report fourth quarter and full year 2024 financial results on March 13

Pharming Group to report fourth quarter and full year 2024 financial results on March 13

Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent

Pharming Group to participate in February investor conference

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

Pharming Group to convene Extraordinary General Meeting of Shareholders

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming announces public cash offer to the shareholders of Abliva AB

Pharming announces public cash offer to the shareholders of Abliva AB

Pharming announces positive topline data in pediatric clinical trial of leniolisib

Pharming announces positive topline data in pediatric clinical trial of leniolisib

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharming Group NV (PHARM) Actualités

Pharming Group NV (PHARM)

Votre Hub pour des idées et discussions en direct en temps réel

PHARM Actualités

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Pharming Group to participate in March investor conference

Pharming Group to report fourth quarter and full year 2024 financial results on March 13

Pharming Group to report fourth quarter and full year 2024 financial results on March 13

Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent

Pharming Group to participate in February investor conference

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

Pharming Group to convene Extraordinary General Meeting of Shareholders

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming announces public cash offer to the shareholders of Abliva AB

Pharming announces public cash offer to the shareholders of Abliva AB

Pharming announces positive topline data in pediatric clinical trial of leniolisib

Pharming announces positive topline data in pediatric clinical trial of leniolisib

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités